The EuroBiotech Journal (Oct 2017)

Genetic testing for Stargardt macular dystrophy

  • Abeshi Andi,
  • Zulian Alessandra,
  • Beccari Tommaso,
  • Dundar Munis,
  • D’Esposito Fabiana,
  • Bertelli Matteo

DOI
https://doi.org/10.24190/ISSN2564-615X/2017/S1.33
Journal volume & issue
Vol. 1, no. s1
pp. 105 – 107

Abstract

Read online

We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for Stargardt macular dystrophy (STGD). STGD is mostly inherited in an autosomal recessive manner and rarely in an autosomal dominant manner, with an overall prevalence of 1-5 per 10 000 live births. It is caused by variations in the ABCA4, CNGB3, ELOVL4, PRPH2 and PROM1 genes. Clinical diagnosis is based on ophthalmological examination, fluorescein angiography, electroretinography, visual field testing, optical coherence tomography and color testing. The genetic test is useful for confirming diagnosis, and for differential diagnosis, couple risk assessment and access to clinical trials.